Developing new methods to create specific amine compounds using metal catalysis.
Stereoselective Transition Metal Catalysis Enabled by Hydrogen-Bond Donor Mediated Electrophile Activation
This study is looking at a new way to make special types of amines that are key ingredients in many medicines, hoping to create better and more effective drugs for patients like you.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard University NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-10995259 on NIH RePORTER |
What this research studies
This research focuses on improving the production of enantioenriched amines, which are important components in many pharmaceuticals. It aims to develop a new method using transition metal catalysis combined with hydrogen-bond donor catalysis to enhance the efficiency and selectivity of chemical reactions. By exploring innovative catalytic processes, the research seeks to overcome limitations of current methods, such as poor reactivity and selectivity. Patients may benefit indirectly through the potential development of more effective medications derived from these improved chemical processes.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research are individuals who require medications that contain enantioenriched amines, such as those with specific health conditions treated by these compounds.
Not a fit: Patients who do not require medications involving enantioenriched amines may not see any direct benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the creation of more effective and targeted medications for various health conditions.
How similar studies have performed: Other research has shown promise in using transition metal catalysis for similar applications, suggesting that this approach could yield significant advancements.
Where this research is happening
Cambridge, United States
- Harvard University — Cambridge, United States (Active)
Researchers
- Principal investigator: Nistanaki, Sepand K — Harvard University
- Study coordinator: Nistanaki, Sepand K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.